Andrew Schiff, MD

Managing Director

Aisling Capital


Dr. Schiff joined Aisling in September of 1999 and currently serves as one of the Managing Partners. Prior to Aisling Capital, Dr. Schiff practiced internal medicine for six years at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine.
Dr. Schiff currently serves as a director of ARMGO Pharma and PowerVision, and as a Board observer of Zavante Therapeutics. Prior Board service includes Adams Respiratory Therapeutics, Agile Therapeutics, ArgiNOx Pharmaceuticals, Barrier Therapeutics, Bioenvision, CardioKine, Cempra Pharmaceuticals, Miramar Labs, Myogen, SkinMedica, Sirion Therapeutics, TransEnterix, Quintiles (Board observer) and ZELTIQ Aesthetics. He is a longtime supporter and Board member of the Visiting Nurse Service of New York. Dr. Schiff received his MD from Cornell University Medical College, his MBA from Columbia University and his BS with honors in Neuroscience from Brown University.